School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Innate Pharma S.A. IPHA

Healthcare · Biotechnology

$1.62last close 2026-10-09 · market cap $180.95M · delayed data

Trailing returns

1M-16.92%
3M-9.50%
6M+11.72%
1Y-20.20%
5Y-73.27%

Basis: Adjusted daily closes.

What it does

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally.

Open IPHA in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies